|
AU2012205123A1
|
|
Methods and reagents for treating infections of clostridium difficile and diseases associate therewith
|
|
CN101394846A
|
|
Treatment of atherosclerotic disease
|
|
CN101395259A
|
|
Rifamycin analogs and uses thereof
|
|
WO2007056086A2
|
|
Rifamycin analogs and uses thereof
|
|
CN101426493A
|
|
Treatment of peripheral arterial occlusive disease
|
|
WO2006080937A2
|
|
Screening assays for antimicrobial agents
|
|
WO2005062882A2
|
|
Rifamycin analogs and uses thereof
|
|
AU2004298983A1
|
|
Rifamycin analogs and uses thereof
|
|
TW200616617A
|
|
Rifamycin analogs and uses thereof
|
|
MXPA06002088A
|
|
Rifamycin analogs and uses thereof.
|
|
CA2508823A1
|
|
Method and reagents for treating or preventing atherosclerosis and diseases associated therewith
|
|
WO2004054513A2
|
|
Methods and compositions for treating and preventing ear infections
|
|
TW200418485A
|
|
Rifalazil compositions and therapeutic regimens
|
|
AU2003268330A1
|
|
Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
|
|
TW200403076A
|
|
Intravenous rifalazil formulation and methods of use thereof
|
|
WO03099217A2
|
|
Methods of treating bacterial infections and diseases associated therewith
|
|
AU2003223309A8
|
|
Polymorphic repetitive sequences in chlamydiae and uses thereof
|
|
AU2002364562A1
|
|
Metal complexes and formulations of rifamycin analogues and uses therof
|
|
WO03051299A2
|
|
Sulfhydryl rifamycins and uses thereof
|
|
AU2002360416A1
|
|
Targeted therapeutics and uses thereof
|
